{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Broxuridine",
  "nciThesaurus": {
    "casRegistry": "59-14-3",
    "chebiId": "CHEBI:472552",
    "chemicalFormula": "C9H11BrN2O5",
    "definition": "A halogenated thymidine analogue with potential antineoplastic and radiosensitizing activities. Bromodeoxyuridine competes with thymidine for incorporation into DNA, resulting in DNA mutation and the inhibition of cell proliferation. As a radiosensitizer, this agent is associated with the inhibition of repair of radiation-induced DNA double-strand breaks.",
    "fdaUniiCode": "G34N38R2N1",
    "identifier": "C318",
    "preferredName": "Broxuridine",
    "semanticType": "Nucleic Acid, Nucleoside, or Nucleotide",
    "subclassOf": [],
    "synonyms": [
      "5-BrdU",
      "5-Bromo-2'-deoxyuridine",
      "5-Bromodeoxyuridine",
      "5-Bromouracil Deoxyriboside",
      "5-Bromouracil deoxyriboside",
      "5-Bromouracil-2-deoxyriboside",
      "5-Budr",
      "BRDU",
      "BROXURIDINE",
      "BrdU",
      "Bromo Deoxyuridine",
      "Bromodeoxyuridine",
      "Bromouracil Deoxyriboside",
      "Bromouracil deoxyriboside",
      "Bromouridine",
      "Broxine",
      "Broxuridine",
      "Neomark",
      "Neomark-BU",
      "broxuridine"
    ]
  }
}